CVS Health reported first-quarter financial results that significantly exceeded analyst expectations for both earnings and revenue, prompting the company to raise its full-year 2026 financial guidance. The positive performance was notably driven by an improvement in its insurance division, Aetna, which has been a focus for investors concerned about rising medical costs.
All of CVS Health's major business segments, including its insurer Aetna, its retail pharmacy operations, and its health services unit, outperformed Wall Street's revenue forecasts. These results signal continued advancement in CVS' comprehensive turnaround strategy. This strategy has encompassed substantial cost-cutting measures, the closure of underperforming retail locations, and adjustments in leadership.
For the full year 2026, CVS Health now anticipates earnings per share to range between $7.30 and $7.50, an upward revision from its prior projection of $7.00 to $7.20 per share. Furthermore, the company projects total revenue to reach at least $405 billion, an increase from the previous outlook of at least $400 billion. CVS Chief Financial Officer Brian Newman indicated that the majority of this $5 billion revenue increase is attributable to positive trends within the Aetna insurance business.
Investors have closely monitored Aetna's performance due to the persistent challenge of high medical costs that have impacted major health insurers over the past two years. The company's ability to deliver stronger results from its insurance arm suggests progress in managing these pressures. CVS' broader turnaround efforts have also included reducing expenses within its privately managed Medicare Advantage plans.
"From an investor lens, we said let's put out realistic, reasonable targets and then find pathways to outperform. And we did that throughout at the end of last year and the quarter," Newman stated in an interview with CNBC. "So to beat and raise, which I think is probably the fourth or fifth consecutive, it feels like we're delivering on that." He expressed confidence in the company's annual performance but maintained a cautious outlook, acknowledging that medical costs remain elevated.
In the first quarter, CVS Health reported adjusted earnings per share of $2.57, surpassing the $2.20 expected by analysts surveyed by LSEG. Revenue for the quarter reached $100.43 billion, exceeding the $95.09 billion consensus estimate. The company's reported net income for the quarter was $2.94 billion, or $2.30 per share, a significant increase from $1.78 billion, or $1.41 per share, in the same period of the prior year.
Excluding specific items such as restructuring charges and capital losses, the adjusted earnings stood at $2.57 per share. The reported sales of $100.43 billion represent a 6.2% increase compared to the first quarter of 2025, with growth observed across all three of CVS' business segments. This performance contributes to a generally positive first quarter for the health insurance sector, although the second quarter will provide further clarity on medical cost trends.
**Insurance Unit Shows Improvement**
The insurance segment, primarily Aetna, generated $35.97 billion in revenue for the first quarter, marking an approximate 3% increase from the first quarter of 2025. This figure also surpassed the $33.28 billion in revenue anticipated by analysts. Newman attributed this outperformance to Aetna's inherent strengths and the implementation of organizational changes aimed at improving efficiency through process and technology enhancements.
Health insurers, including Aetna, have faced headwinds from higher-than-anticipated medical costs, particularly as Medicare Advantage members resume seeking procedures deferred during the pandemic. While medical costs persist at high levels, insurers appear to be adapting their strategies. Many have adjusted membership, benefits, and market participation to better manage these costs. The medical benefit ratio for CVS' insurance segment, which measures medical expenses against collected premiums, improved to 84.6% from 87.3% in the prior year. Analysts had projected a ratio of 86.3%.
Newman emphasized that while medical costs have not decreased, CVS has developed internal programs to enhance operational efficiency and reduce expenses. He noted an improved ability to forecast medical cost trends, stating satisfaction that the company is experiencing fewer unexpected cost increases. The next critical step, he added, is to leverage these forecasting tools to actively reduce medical expenditures.
In its official release, CVS also highlighted that the year-over-year improvement in the insurance unit was partly due to the absence of a premium deficiency reserve that was recorded in the first quarter of 2025. Such a reserve is established when an insurer anticipates that future premiums may not be sufficient to cover projected claims and expenses.
The company's pharmacy and consumer wellness division, which includes its extensive network of over 9,000 retail pharmacies dispensing prescriptions and offering services like vaccinations and diagnostic testing, recorded $31.99 billion in sales. This was largely in line with the $31.70 billion expected by analysts. This segment plays a crucial role in delivering accessible healthcare services directly to consumers.
CVS' health services segment, encompassing its pharmacy benefits manager (PBM) Caremark, reported revenue of $48.24 billion, an 11% increase compared to the same period in the previous year. Caremark is instrumental in negotiating drug prices with manufacturers, establishing formularies that dictate covered medications, and processing reimbursements for pharmacies. The robust growth in this segment underscores its importance in CVS' integrated healthcare model, contributing significantly to the company's overall financial strength and strategic positioning in the market.
Shares of CVS Health saw a notable increase, rising more than 7% on Wednesday following the release of the strong quarterly results and the upward revision of the company's financial outlook. This market reaction reflects investor confidence in CVS' ongoing turnaround efforts and its ability to navigate the complex healthcare landscape.
